In this article, we will list the 5 Fastest Growing Tech Penny Stocks to Buy. Please visit 10 Fastest Growing Tech Penny Stocks to Buy if you would like to see the extended list and the methodology behind it.
5. Gloo Holdings, Inc. (NASDAQ:GLOO)
On July 9, 2026, Gloo Holdings, Inc. (NASDAQ:GLOO) priced a 7M share secondary at $3.25. The deal is priced below the last closing price of $3.98. JPMorgan is acting as the sole book-running manager for the offering.
On June 9, Benchmark raised the firm’s price target on Gloo to $15 from $14 and kept a Buy rating on the shares after “yet another beat and raise” in fiscal Q1. Benchmark called Gloo “an unchallenged leader” in the faith and flourishing space and continued to view the stock as one of the more compelling risk/reward opportunities in its coverage.
Also on June 9, Gloo reported Q1 EPS of (21c), compared with estimates of (18c), and revenue of $41.5M, compared with consensus of $36.0M. CEO Scott Beck said AI remains a “force multiplier” behind the company’s platform and said the quarter exceeded guidance and analyst consensus.
Gloo Holdings, Inc. (NASDAQ:GLOO) designs and develops a vertical technology platform for the faith and flourishing ecosystem.
4. Autolus Therapeutics plc (NASDAQ:AUTL)
On July 1, 2026, Autolus Therapeutics plc (NASDAQ:AUTL) announced that the Compensation Committee of its Board of Directors granted stock option awards to purchase an aggregate of 25,420 American Depositary Shares and 87,530 restricted stock units to 13 employees under the company’s 2025 Inducement Plan. The awards were granted as inducement material to the individuals becoming employees of Autolus in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option awards and RSUs have a grant date of June 24, 2026. The stock options have an exercise price of $1.66 per share, equal to the closing price of Autolus’ common stock on June 23, 2026. Each stock option award has a ten-year term and vests over four years, while each RSU vests in four equal annual installments, subject to continued service through the applicable vesting dates.
Over a month ago, H.C. Wainwright raised the firm’s price target on Autolus Therapeutics to $10 from $9 and kept a Buy rating on the shares after the Q1 report. H.C. Wainwright said the company’s Aucatyzl U.S. demand is growing, while the UK launch is off to a positive start.
Autolus Therapeutics plc (NASDAQ:AUTL) develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally.
3. Ovid Therapeutics Inc. (NASDAQ:OVID)
On July 8, 2026, Ovid Therapeutics Inc. (NASDAQ:OVID) announced several strategic appointments. Kevin Norrett will join Ovid as chief business officer to lead business and corporate development functions, as well as strategic partnerships. Most recently, Norrett served as chief business officer at Soleno Therapeutics.
Ovid also promoted Charles Carter to CFO, where Carter will lead business and financial operations. Carter succeeds Jeffrey Rona, who will remain a long-term advisor to the company through 2027. Victoria Fort was promoted to chief strategy officer, leading enterprise strategy, investor relations, and operational growth initiatives.
In May, Ovid Therapeutics reported Q1 EPS of (12c), compared with the consensus of (11c). CEO Meg Alexander said the first quarter reflected “focused execution” and continued progress across the company’s pipeline of small molecule medicines for intractable brain conditions. Alexander said development programs remain on track, the clinical organization has expanded, and the company expects to be well capitalized into 2029.
Ovid Therapeutics Inc. (NASDAQ:OVID) develops small-molecule medicines for brain disorders, including epilepsies and seizure-related neurological disorders in the United States.
2. Cibus, Inc. (NASDAQ:CBUS)
On June 17, 2026, Cibus, Inc. (NASDAQ:CBUS) welcomed a landmark European Union decision under which crops improved without adding foreign DNA will be treated like conventionally bred crops rather than transgenic GMOs. Cibus said the decision opens a path for European farmers to grow cleaner crops more productively, including by fighting disease and pests with fewer chemicals.
Cibus said the new rules draw a line between transgenic GMOs, which add foreign DNA, and the precise, non-transgenic improvements Cibus makes to a plant’s own genes. The company said crops that resist disease, use water and nutrients more efficiently, and require fewer chemicals qualify for the framework’s non-GMO fast lane, where they are treated the same as conventionally bred crops. President and COO Peter Beetham said the E.U. completed a “science-based review” and recognized that crops with changes that could occur in nature or through traditional breeding should be regulated accordingly.
On June 9, Cibus announced leadership changes under its previously announced succession planning strategy. Craig Wichner, a board member since November 2025, was appointed CEO. Peter Beetham, who served as Interim CEO, will continue as President and COO. Wichner and Beetham also resigned from the Cibus Board of Directors as part of the reorganization and plan.
Cibus, Inc. (NASDAQ:CBUS) is an agricultural biotechnology company that develops and licenses gene-edited plant traits.
1. Datavault AI Inc. (NASDAQ:DVLT)
On July 9, 2026, Datavault AI Inc. (NASDAQ:DVLT) signed a three-party joint venture agreement with Unity Reserve and Mandela Dlamini, or MDM LLC, forming Mandela Digital. The venture is developing the Mandela Dollar, or MUSD, a proposed 1:1 USD-backed stablecoin designed to advance financial inclusion across the Global South and beyond. Under the agreement, Datavault AI becomes Mandela Digital’s founding and exclusive technology partner, deploying its full technology stack to power the venture.
Also on July 9, Datavault AI announced that the United States Patent and Trademark Office issued a Notice of Allowance, dated July 1, for U.S. Patent Application No. 19/445,241, “Method and System for Mitigating Naked and Excessive Short Selling through Tokenized Dividend Distribution.” The notice allowed all 24 pending claims. The company said the application was filed on January 9, 2026, reaching allowance in under six months, and that the allowed claims address how issuers and shareholders can verify ownership and dividend entitlement when settlement discrepancies obscure the true share count.
Earlier in July, Datavault AI announced a proposed strategic partnership with Patriot Strategic Metals to jointly develop the Strategic Materials Acquisition Platform. The platform is designed to support the financing, tokenization, settlement, and lifecycle management of strategic mineral assets. CEO Nathaniel Bradley said the partnership brings together physical strategic assets and Datavault AI’s “institutional grade cyber secure digital infrastructure,” while combining PSM’s critical minerals platform with Datavault AI’s patented RWA technology.
Datavault AI Inc. (NASDAQ:DVLT) owns and operates data management platforms with high computing capabilities in North America, Asia Pacific, Europe, and internationally.
While we acknowledge the potential of DVLT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than DVLT and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 10 Fastest Growing Asian Stocks to Buy Now and 12 High Quality Stocks to Buy for the Long Term.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
